Trilaciclib Approved for Chemo-Induced Myelosuppression in Small-Cell Lung Cancer

The FDA has approved trilaciclib (CoselaTM, G1 Therapeutics) for the prevention of myelosuppression in patients receiving chemotherapy for extensive-stage small-cell lung cancer (SCLC). Occurring when chemotherapy agents damage the bone marrow, myelosuppression decreases the production of red blood cells, white blood cells, and platelets, causing patients to experience fatigue, bleeding, and increased risk of infection. "Chemotherapy is a mainstay of cancer treatment; however, its side effects, ...
Continue reading

E-Cigarettes and Bladder Cancer Risk: Marc Bjurlin, DO, MSc

Despite their known pulmonary, neurological, and carcinogenic risks, electronic cigarette (e-cigarette) use has increased drastically in recent years, especially among adolescents and young adults. In a recent study, a team of researchers led by Marc Bjurlin, DO, MSc, Associate Professor of Urology at the University of North Carolina Chapel Hill's Lineberger Comprehensive Cancer Center, analyzed the urine samples of e-cigarette users and identified the presence of several carcinogenic biomarkers...
Continue reading

Could E-Cigarettes Cause Bladder Cancer?

According to the results of a recently published study, carcinogenic biomarkers strongly linked to bladder cancer risk are found in the urine samples of electronic cigarette (e-cigarette) users. E-cigarettes contain nicotine, additives, and other chemical solvents that can create numerous toxic compounds when heated. Their popularity has increased dramatically in recent years, especially in the adolescent and young adult population. Between 2017 and 2018, usage increased nearly 80% among high sc...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts